EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro

Rhodri Harfoot, Blair Lawley, Leonor C Hernández, Joanna Kuang, Francesca R Hills, Shubhra Sinha, Margot J M Allais, Tom W Bird iD, Cody P Hird, John A Taylor, Mihnea Bostina iD, Davide Comoletti und 4 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01700-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Rhodri Harfoot und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: SARS-CoV-2, Virus Replication, Antiviral Agents, Antimicrobial Cationic Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Business, Innovation and Employment, Ministry of Health, New Zealand, Western Research Chair in Viral Pathogenesis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although myriads of potential antiviral agents have been tested against SARS-CoV-2, only a handful have proven to be effective in clinical trials. During the COVID-19 pandemic, many known or novel peptides were evaluated for their ability to inhibit SARS-CoV-2 replication; however, testing of D-enantiomers that resist body and viral proteases has been limited. Here, we characterized the ability of D-3006, a D-enantiomeric synthetic host defense peptide, to inhibit SARS-CoV-2 replication in vitro . A battery of authentic SARS-CoV-2 variants (ancestral, Mu, Delta, and Omicron BA.1) and a comprehensive panel of β-coronavirus spike pseudotyped lentiviruses were used to demonstrate that D-3006 safely (CC 50 value = 430 µg/mL) blocked spike-mediated entry (EC 50 values ranging from 1.57 to 5.37 µg/mL) and also had synergistic anti-SARS-CoV-2 activity in vitro when combined with the viral polymerase inhibitor remdesivir. We also showed that D-3006 inhibited influenza A virus (H1N1) replication in vitro , suggesting that this synthetic host defense peptide could have potential broad antiviral activity against multiple enveloped viruses. These data, together with negative-stain transmission electron microscopy analysis, suggest that the mechanism of action of D-3006 is associated with non-specific binding to the viral membrane, most likely causing virus aggregation and interfering with virus attachment and entry. The potential broad-spectrum antiviral activity of D-3006, its innate resistance to host proteases, as well as the possibility of being used in combination with other antiviral drugs suggest that this host synthetic peptide could be developed as a candidate for the treatment of SARS-CoV-2 and/or other respiratory viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Virus ReplicationAntiviral AgentsAntimicrobial Cationic PeptidesHumansCOVID-19 Drug TreatmentVirus InternalizationVero CellsSpike Glycoprotein, CoronavirusCOVID-19AnimalsChlorocebus aethiopsAdenosine MonophosphateAlanineHEK293 Cells

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviralhost defense peptidesinfluenza virus

Substanzen

Antiviral AgentsremdesivirSpike Glycoprotein, CoronavirusAntimicrobial Cationic PeptidesAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
  • Department of Pediatric Dentistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • School of Biomedical Sciences, Victoria University of Wellington, Wellington, New Zealand.
  • Institute of Environmental Science and Research, Wellington, New Zealand.
  • Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, London, Ontario, Canada.
  • School of Biological Sciences, The University of Auckland, Auckland, New Zealand.

ORCID-Profile: Tom W Bird, Mihnea Bostina, Robert E W Hancock, Daniel Pletzer, Miguel E Quiñones-Mateu

Förderung

  • Ministry of Business, Innovation and Employment
  • Ministry of Health, New Zealand
  • Western Research Chair in Viral Pathogenesis
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Harfoot, R., Lawley, B., Hernández, L. C., Kuang, J., Hills, F. R., Sinha, S., Allais, M. J. M., Bird, T. W., Hird, C. P., Taylor, J. A., Bostina, M., Comoletti, D., Haney, E. F., Hancock, R. E. W., Pletzer, D., & Quiñones-Mateu, M. E. (2025). Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01700-24

Vancouver

Harfoot R, Lawley B, Hernández LC, Kuang J, Hills FR, Sinha S, et al. Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01700-24

BibTeX
@article{Harfoot2025,
  author = {Harfoot, Rhodri and Lawley, Blair and Hernández, Leonor C and Kuang, Joanna and Hills, Francesca R and Sinha, Shubhra and Allais, Margot J M and Bird, Tom W and Hird, Cody P and Taylor, John A and Bostina, Mihnea and Comoletti, Davide and Haney, Evan F and Hancock, Robert E W and Pletzer, Daniel and Quiñones-Mateu, Miguel E},
  title = {Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01700-24}
}
Kostenlos starten →